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Abstract: Defects in the extracellular matrix protein fibrillin-1 that perturb transforming growth
factor beta (TGFβ) bioavailability lead to Marfan syndrome (MFS). MFS is an autosomal-dominant
disorder, which is associated with connective tissue and skeletal defects, among others. To date, it
is unclear how biological sex impacts the structural and functional properties of bone in MFS. The
aim of this study was to investigate the effects of sex on bone microarchitecture and mechanical
properties in mice with deficient fibrillin-1, a model of human MFS. Bones of 11-week-old male and
female Fbn1mgR/mgR mice were investigated. Three-dimensional micro-computed tomography of
femora and vertebrae revealed a lower ratio of trabecular bone volume to tissue volume, reduced
trabecular number and thickness, and greater trabecular separation in females vs. males. Three-point
bending of femora revealed significantly lower post-yield displacement and work-to-fracture in
females vs. males. Mechanistically, we found higher Smad2 and ERK1/2 phosphorylation in females
vs. males, demonstrating a greater activation of TGFβ signaling in females. In summary, the present
findings show pronounced sex differences in the matrix and function of bones deficient in fibrillin-1
microfibrils. Consequently, sex-specific analysis of bone characteristics in patients with MFS may
prove useful in improving the clinical management and life quality of these patients, through the
development of sex-specific therapeutic approaches.
Keywords: biomechanics; bone architecture; fibrillin; Marfan syndrome; sex; TGFβ signaling
1. Introduction
Microfibrils and elastic fibers are the primary components of the architectural scaffold of connective
tissue [1]. Fibrillin molecules—together with other extracellular matrix proteins—make up microfibrils
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and regulate microfibril biogenesis and function [2]. Gene defects in fibrillin-1 give rise to Marfan
syndrome (MFS; OMIM #154700). MFS is an autosomal-dominant connective-tissue disorder, primarily
characterized by musculoskeletal, ocular, pulmonary and cardiovascular anomalies, affecting about
2–3 in every 10,000 individuals [3,4]. The severity of clinical manifestations and the age of onset vary
widely. Mutations in fibrillin-1 lead to severe skeletal abnormalities, including malformations of the
limbs, spine and anterior chest wall [5]. Although reduced bone mass (osteopenia) is a controversial
finding in MFS [2], decreases in bone mineral density (BMD) have been reported in adult patients [6–9]
and children with MFS [9–12].
In many frequent pathological conditions, there are significant differences between men and
women [13,14]. In the literature, we found only a few studies of adult patients with MFS that present
data separately for each sex. In these limited reports, we observed that women appear to have, for
example, lower BMD values than men [8,15]. However, whether this is true and a general phenomenon
in MFS patients is not known, as any sex differences in MFS have not been systematically investigated.
Mice harboring a mutation in the Fbn1 gene (Fbn1mgR/mgR) model a progressive form of human
MFS [16]. MFS-associated skeletal anomalies have been documented in this and other mouse models
of fibrillin-1 disruption [5]. In particular, Fbn1mgR/mgR mice develop osteopenia [17], i.e., reduced
BMD. Although age-related changes in trabecular architecture differ between healthy male and female
C57BL/6J mice [18], it is not understood whether there are any differences between male and female
MFS mice in terms of bone structural and functional properties.
In the present study, in order to address this knowledge gap, we aimed at characterizing the
bone microarchitecture and functional properties of male and female Fbn1mgR/mgR mice, hypothesizing
pronounced sex differences. Considering that MFS is associated with transforming growth factor beta
(TGFβ) over-activation [3,4,19], we also assessed the regulation of TGFβ signaling as a mechanistic
factor contributing to sex-specific skeletal manifestations of MFS.
2. Results
2.1. Study Design and Body Mass
In the present study, we sought to investigate the effects of sex on the bone microarchitecture and
functional properties of adult mice with deficient fibrillin-1. For this purpose, we employed male and
female Fbn1mgR/mgR mice, a model of human MFS, which have an average survival period of ca. 4
months [16]. Based on this, we initially planned to study eight male and eight female Fbn1mgR/mgR mice
at the age of 11 weeks. During the course of the study, there were three deaths in the male group and
two deaths in the female group. At 11 weeks of age, the female Fbn1mgR/mgR mice weighed significantly
less than the male Fbn1mgR/mgR mice (Figure 1).
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2.2. Bone icroarchitecture
To determine the effects of sex on bone composition, we evaluated the microarchitecture of
femora and vertebrae from male and female Fbn1mgR/mgR mice using micro-computed tomography
(µCT). Our analysis revealed no significant differences between ale and fe ale fe ora in cortical
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bone parameters (Figure 2A,C). In contrast, there were significant sex differences in the trabecular
microarchitecture of femora (Figure 2B,D). In particular, the trabecular bone volume fraction, thickness
and number were significantly lower in female femora compared with male femora, while trabecular
separation was significantly higher in female femora compared with male femora (Figure 2B,D).
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Figure 2. Cortical and trabecular architecture of fem ra from male (n = 5) a d female (n = 6)
Fbn1mgR/mgR mice as determined by micro-computed tomography (µCT). (A) Representative µCT
images of cortical bone cross sections (top) and 3D reconstructions showing cortical bone (bottom). (B)
Representative µCT images of trabecular bone cross sections (top) and 3D reconstructions showing
trabecular architecture (bottom). (C) Qu ntification of cortical parameters at the femoral diaphysis.
(D) Quantification of trabecular parameters at the distal fe oral metaphysis. BV/TV, % bone volume;
Co.Th, cortical thickness; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular
thickness. Data present mean ± SEM; **p < 0.01.
Similarly to the femora, there were marked sex differences in the trabecular architecture of the
vertebrae (Figure 3). There was a strong trend for lower trabecular bone volume fraction in female
vertebrae compared with male vertebrae, which, however, did not reach statistical significance (p = 0.1).
The trabecular bone number was significantly lower in female vertebrae compared with male vertebrae,
while the trabecular separation was significantly higher in female vertebrae compared with male
vertebrae (Figure 3). There was no difference in trabecular bone thickness.
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2.3. Whole-Bone Mechanical Properties
To determine the effects of sex on mechanical properties, we subjected femora from male and
female Fbn1mgR/mgR mice to biomechanical testing via 3-point bending. Our analysis revealed that
the maximum load did not differ between male and female femora (Figure 4A). However, female
femora had significantly greater stiffness compared with male femora (Figure 4B), hile post-yield
displacement and work-to-fracture were significantly lower in female femora compared with male
femora (Figure 4C,D).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 11 
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2.4. TGFβ Signaling
To understand the underlying mechanisms contributing to differences in bone properties between
male and female Fbn1mgR/mgR mice, we assessed the activation of TGFβ signaling by measuring the
phosphorylation of Smad2 and Erk1/2, the relevance of which in MFS has been shown [3,4,19]. In
line with our hypothesis of elevated TGFβ signaling in females vs. males, immunoblotting analysis
revealed significantly higher levels of phosphorylated Smad2 and Erk1/2 in female tibiae compared
with male tibiae (Figure 5).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 11 
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Figure 5. Assessment of transforming growth factor beta (TGFβ) pathway markers. The detection of
phosphorylated and total Smad2 (A), and phosphorylated and total Erk1/2 (B), by immunoblotting
with Gapdh as a loading control, as well as the corresponding quantification in tibiae from male (n = 5)
and female (n = 5) Fbn1mgR/mgR mice, is shown. Data present mean ± SEM; *p < 0.05; AU, arbitrary unit.
3. Discussion
In the present study, we investigated the role of sex in microarchitecture and mechanical properties
of bones at axial and appendicular sites in male and female mice harboring a mutation in the Fbn1
gene (Fbn1mgR/mgR), a model of human MFS. To our knowledge, this is the first study reporting
significant differences in trabecular bone and mechanical properties of femora between male and
female Fbn1mgR/mgR mice. In addition, our biochemical analysis revealed significant sex differences that
may contribute to the mechanisms impacting bone quality in a sex-specific manner.
Although there were no major sex differences in cortical bone microarchitecture parameters of
femora, the trabecular bone phenotype differed significantly between male and female Fbn1mgR/mgR mice.
In particular, compared with male Fbn1mgR/mgR mice, female Fbn1 gR/mgR mice displayed significant
reductions in trabecular bone volume fraction, thickness and trabecular number, as well as a significant
increase in trabecular separation. Sex differences in trabecular architecture at the vertebrae followed
similar patterns as the femora. Together, these data indicate that there are pronounced sex differences
in metabolic signals among osteocytes and osteoclasts, leading to sex-specific bone mass phenotypes.
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Our whole-bone biomechanical analysis revealed that there were no sex differences in the
maximum load before fracture. However, stiffness was significantly higher in female femora than
in male femora, while post-yield displacement was significantly lower in female femora than in
male femora. Along this line, the overall resistance to failure—as assessed by work-to-fracture—was
significantly lower in female femora compared with male femora. These findings indicate that female
femora present brittle behavior that may be more prone to fracture.
To elucidate underlying mechanisms contributing to sex-specific bone remodeling in Fbn1mgR/mgR
mice, we verified the activation of TGFβ signaling, assessing the phosphorylation levels of Smad2 and
Erk1/2. Our analysis revealed that the levels of phosphorylated Smad2 and Erk1/2 were significantly
higher in female tibiae when compared with male tibiae. Normal fibrillin-1, which forms extracellular
microfibrils, is involved in regulating the bioavailability of TGFβ [20]. However, defects in fibrillin-1
in MFS disturb this regulatory mechanism, causing the activation of TGFβ signaling, which, in
turn, leads to the phosphorylation of the downstream signal transducers Smad2 and Erk1/2 [21,22].
Notably, decreased bone volume and density in Fbn1mgR/mgR mice was reported to be due to increased
osteoclastogenesis, which was largely attributed to the activation of TGFβ signaling [17]. Therefore,
the present findings indicate that there is a greater activation of TGFβ signaling in female vs. male
Fbn1mgR/mgR mice, which may underlie the sex differences in microarchitecture and mechanical
properties of bones in this model of human MFS.
Our analysis was limited to one age (11 weeks), and to femora, tibiae and vertebrae. Therefore,
these data may not extrapolate to animals of other ages or other parts of the skeleton. However, the
comparisons presented here demonstrate, for the first time, a role of sex in microarchitecture and
mechanical properties of bones at axial and appendicular sites in Fbn1mgR/mgR mice. The major driver
of the sex differences reported here is also not clear. We speculate that estrogen may play an important
role, and it would be worth examining these findings in estrogen-depleted and -treated animals to
test this hypothesis. In addition, considering previous findings in relation to the heart—where the
response to treatment may differ significantly between the sexes [23,24] or between different genetic
backgrounds [25]—and the contribution of multiple genetic variations to disease development and
drug responses [26,27], it would be of interest to determine the role of sex in bone remodeling using
different animal models of MFS. Furthermore, although the role of aberrant TGFβ signaling in the
pathophysiology of MFS is well established, there is an incomplete understanding of the contributing
mechanisms [28], particularly in MFS-associated skeletal pathophysiology. Moreover, the objective
of this analysis was focused on comparing male and female Fbn1mgR/mgR mice directly and not with
wild-type mice. Therefore, it cannot be excluded that some of the differences observed here might
reflect physiological skeletal differences between males and females as described previously for healthy
C57BL/6J mice [18]. Further research is therefore warranted.
4. Materials and Methods
4.1. Experimental Animals
Male and female Fbn1mgR/mgR (n = 16) mice were employed and genotyped as described
previously [16]. The heterozygous mutant progeny was originally provided by Dr. Francesco
Ramirez and the animals analyzed in this study come from a colony held on our site [29]. The mice
were kept on a 12–12 h light–dark cycle in temperature-controlled rooms with water ad libitum. At 11
weeks of age, the mice were euthanized and the long bones—the femora and tibiae—as well as the
vertebrae, were collected, stripped of soft tissues and prepared for µCT, or wrapped in saline-soaked
gauze and frozen at −20 ◦C (for biomechanical testing), or snap frozen in liquid nitrogen and stored at
−80 ◦C (for immunoblotting), until further analyses were performed. All experiments were performed
following the guidelines of the EU Directive 2010/63/EU for animal experiments, and were approved
by the Landesamt für Gesundheit und Soziales, Berlin, Germany (Nr. G0090/14, 01.08.2014).
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4.2. Micro-Computed Tomography
Three-dimensional micro-computed tomography (µCT) analysis was performed on femora and
vertebrae. One femur and the third lumbar vertebral body from each animal were scanned using the
vivaCT40 scanner (SCANCO Medical AG, Brüttisellen, Switzerland). For all scans, a resolution of 10.5
µm, a voltage of 70 kV, a current of 114 µA, and a 0.5 mm aluminum filter were used. The scans were
analyzed with Fiji (ImageJ, Bethesda, MD, USA [30]). Image stacks were aligned using landmarks and
the volume of interest (VOI) was set. For trabecular bone parameters, the starting point of the VOI was
set at the distal femur, directly at the end of the growth plate, with a diameter of 0.75 mm and a height
of 1.5 mm. To analyze cortical parameters of the femur diaphysis, the VOI started 5 mm proximally of
the VOI for trabecular bone, with a height of 5 mm including the complete cortical area. The VOI for
the vertebrae was the same defined cylinder as for the trabecular bone of the femur and was set exactly
in the middle of the third lumbar vertebral body.
4.3. Biomechanical Measurement
The biomechanical whole-bone strength was analyzed in destructive three-point bending
experiments, using a Bose Test Bench LM 1 ElectroForce (Bose, Eden Prairie, MN, USA). Femora were
mounted anterior side up for bending tests at an 8.5 mm span width between the end supports. The
load was applied to the anterior midshaft of the femora at a constant deflection rate of 0.1 mm/s. Load
(50 lbs/225 N load cell) and displacement data were acquired at 100 Hz. Stiffness, load, deflection
and work were calculated from the force-deflection curve using a routine written in MATLAB (The
Mathworks Inc., Natick, MA, USA). Whole-bone mechanical properties were adjusted for body mass
using the linear regression method, according to the guidelines described previously [31].
4.4. Immunoblotting
Protein lysates were isolated from tibiae as described previously [32–34]. Independent biological
replicates for each group were run separately on SDS-PAGE gels and transferred to nitrocellulose
membranes using standard procedures. Primary antibodies against pSmad2, Smad2, pErk1/2, Erk1/2
(all from Cell Signaling Europe, Frankfurt am Main, Germany), and Gapdh (Thermo Fisher, Darmstadt,
Germany; loading control) were used. For immunodetection, secondary antibody donkey anti-rabbit
or anti-mouse (Dianova, Hamburg, Germany) and ECL™ Prime Western Blotting Reagent (Amersham,
Munich, Germany) were used. Data were quantified with the ImageJ software version 1.52a (http:
//rsbweb.nih.gov/ij/).
4.5. Statistical Analysis
All data are presented as mean ± SEM. Statistical significance was assessed using PRISM version
7 (GraphPad Software Inc., San Diego, CA, USA). Comparisons between two groups were made with
non-parametric Mann–Whitney U tests. p ≤ 0.05 was considered significant.
5. Conclusions
Whether there are any sex differences in bone mass and matrix properties of human MFS patients
is not known. The present study shows that the bone microarchitecture and functional properties of
mice with deficient fibrillin-1 differ significantly between males and females. Consequently, these
findings call for a sex-specific analysis of bone characteristics (and fractures) in patients with MFS. As
no cure is available, current treatment strategies target the improvement of patients’ symptoms through
pharmacological approaches, to tackle primarily pulmonary and cardiovascular phenotypes. However,
there are studies indicating that not all MFS patients may respond to such treatments, which may
also not be effective against some manifestations of MFS, such as those affecting the skeleton [35–37].
Given that there may be pronounced sex differences in responses to pharmacological interventions [27],
it is necessary to determine the role of sex in standard treatment strategies used with MFS patients.
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Artificial intelligence, by means of in silico models, may be useful in predicting sex-specific drug
responses, thereby facilitating their translation into clinical practice [38,39]. Lastly, due to the clear
need for the development of novel and effective strategies addressing the skeletal abnormalities in MFS,
we put forward that sex-specific therapies would contribute to more appropriate and personalized
medical care, thereby addressing the needs of male and female patients.
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